VLL Q2 Financial Results

Financial Results for 31.03.2022

Consolidated Financials for 31.03.2023

Standalone Financials for 31.03.2023

Credit Rating - November 2023

COC for Independent director

Code of conduct

CSR Policy

Materiality

Nomination and Remuneration policy

Policy on determination of material subsidiary

Policy on determination of materiality of event

Preservation and Archival

Prevention of Sexual Harassment at Workplace

RPT Policy

UPSI

Vigil mechanism policy

CRISIL Industry Report

Valiant RHP

Valiant DRHP

Prospectus

Consent of Promoters,Directors,CS,CFO,RTA,Legal,BRLM,Banker

KPI

Orbit Consultant 28.08.23 CE Certificate

Working capital Assessment

Consent from statutory auditor

CRISIL Consent Letter Valiant Labs May 2023

Examination CFS Audit report

Examination SFS Audit report

Statement of Tax Benefits

Certificate of Incorporation VLL

IPO Monitoring Agency dated September 07, 2023

VLL RTA Agreement dated May 30, 2023

VLL Annual Report 22-23

VLL 21-22 Annual Report

RHP Resolution adoption

Cash escrow agreement dated September 13, 2023

Syndicate agreement dated September 13, 2023

CRISIL Assessment of pharmaceutical API and speciality chemicals industry 30.05.2023

Valiant Labs MOA AOA

NSE In principle approval letter august 25, 2023

BSE In principle approval letter august 25, 2023

SEBI letter dated June 28, 2023

SEBI letter dated September 12, 2023

Due Diligence certificate with IIIA

Regulation Wise Checklist IIIB

Tripartite Agreement CDSL

Tripartite Agreement NSDL

Members IPO Resolution dated March 20, 2023

Adoption of DRHP dated June 05, 2023

Board IPO Resolution dated January 30, 2023

Resolution approving objects of the Issue dated may 23, 2023

Shareholders amendment agreement dated May 30, 2023

Shareholders agreement dated June 15, 2022

IPO Issue Agreement dated June 05, 2023

Board-Meeting-Intimation-30.09.2023